These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 25126339)

  • 1. Comparative effectiveness research in the United States: a catalyst for innovation.
    Ali R; Hanger M; Carino T
    Am Health Drug Benefits; 2011 Mar; 4(2):68-72. PubMed ID: 25126339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How the Recovery Act's Federal Coordinating Council paved the way for the Patient-Centered Outcomes Research Institute.
    Conway PH
    Health Aff (Millwood); 2010 Nov; 29(11):2091-7. PubMed ID: 20923814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of comparative effectiveness research on interventional pain management: evolution from Medicare Modernization Act to Patient Protection and Affordable Care Act and the Patient-Centered Outcomes Research Institute.
    Manchikanti L; Falco FJ; Benyamin RM; Helm S; Parr AT; Hirsch JA
    Pain Physician; 2011; 14(3):E249-82. PubMed ID: 21587337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness research (CER): a summary of AHRQ's CER on therapies for rheumatoid arthritis.
    Oderda GM; Balfe LM
    J Manag Care Pharm; 2011; 17(9 Suppl B):S19-24. PubMed ID: 22073936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging lessons from regional and state innovation in value-based payment reform: balancing collaboration and disruptive innovation.
    Conrad DA; Grembowski D; Hernandez SE; Lau B; Marcus-Smith M
    Milbank Q; 2014 Sep; 92(3):568-623. PubMed ID: 25199900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness regulations and pharmaceutical innovation.
    Vernon JA; Golec JH; Stevens JS
    Pharmacoeconomics; 2010; 28(10):877-87. PubMed ID: 20831295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the long-term impact of public investments in comparative effectiveness research: conceptual framework and lessons learned.
    Rich EC; Esposito D; Kimmey LD; Valenzano CS; Yong PL
    J Comp Eff Res; 2014 Nov; 3(6):657-66. PubMed ID: 25494572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of recent federal spending on comparative effectiveness research: priorities, gaps, and next steps.
    Benner JS; Morrison MR; Karnes EK; Kocot SL; McClellan M
    Health Aff (Millwood); 2010 Oct; 29(10):1768-76. PubMed ID: 20921474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness research under the Patient Protection and Affordable Care Act: can new bottles accommodate old wine?
    Kinney ED
    Am J Law Med; 2011; 37(4):522-66. PubMed ID: 22292212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AMCP Partnership Forum: What's Next for Specialty Medication Benefit Design and Reimbursement.
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1206-1213. PubMed ID: 32780612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. States Encouraging Value-Based Payment: Lessons From CMS's State Innovation Models Initiative.
    Kissam SM; Beil H; Cousart C; Greenwald LM; Lloyd JT
    Milbank Q; 2019 Jun; 97(2):506-542. PubMed ID: 30957292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facts, fallacies, and politics of comparative effectiveness research: Part I. Basic considerations.
    Manchikanti L; Falco FJ; Boswell MV; Hirsch JA
    Pain Physician; 2010; 13(1):E23-54. PubMed ID: 20119474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How the Patient-Centered Outcomes Research Institute can best influence real-world health care decision making.
    Garber AM
    Health Aff (Millwood); 2011 Dec; 30(12):2243-51. PubMed ID: 22147851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Building electronic data infrastructure for comparative effectiveness research: accomplishments, lessons learned and future steps.
    Randhawa GS
    J Comp Eff Res; 2014 Nov; 3(6):567-72. PubMed ID: 25494561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond "safe and effective": the role of the federal government in supporting and disseminating comparative-effectiveness research.
    Francis MH
    Ann Health Law; 2012; 21(2):329-82, 5 p preceding i. PubMed ID: 22606919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and implementation of health technology assessment in Argentina: two steps forward and one step back.
    Rubinstein A; Pichon-Riviere A; Augustovski F
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():260-9. PubMed ID: 19527545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMCP Partnership Forum: Designing Benefits and Payment Models for Innovative High-Investment Medications.
    J Manag Care Spec Pharm; 2019 Feb; 25(2):156-162. PubMed ID: 30698091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American Recovery and Reinvestment Act-comparative effectiveness research infrastructure investments: emerging data resources, tools and publications.
    Segal C; Holve E
    J Comp Eff Res; 2014 Nov; 3(6):647-55. PubMed ID: 25494571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nine years of comparative effectiveness research education and training: initiative supported by the PhRMA Foundation.
    Devine EB; Perfetto E; Pickard AS; Schumock GT; Segal JB; Cannon E; Gagnon JP; Brixner DI; Garrison LP; Murray MD
    J Comp Eff Res; 2018 Feb; 7(2):167-175. PubMed ID: 29464964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.